The integration of epigenomic profiling in clinical diagnostics may guide the choice of epigenetic therapy – an approach already employed when giving IDH inhibitors to IDH-mutant AML or considering Menin inhibitors for MLL/NPM1 cases. This evidence concerns the gene KMT2A and acute myeloid leukemia.